Contribute Try STAT+ Today

A coalition of consumer groups and unions hopes to convince the Federal Trade Commission to alter the terms of AbbVie’s (ABBV) proposed $63 billion acquisition of Allergan (AGN) by arguing the deal — as currently conceived — would thwart competition and unfairly maintain higher drug prices for consumers.

In a letter to the agency Tuesday, the coalition contends that allowing Allergan to divest an experimental medicine for treating Crohn’s disease and ulcerative colitis to AstraZeneca (AZN) would fail to ensure the market for such medicines would be fully competitive. The companies last month proposed to divest the drug, brazikumab, and one other in a bid to satisfy regulatory concerns about the acquisition.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Your daily dose of news in health and medicine

Privacy Policy